Advertisement

Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Document › Details

Bayer Corporation. (11/26/18). "Press Release: FDA Approves Vitrakvi (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion". Whippany, NJ & Stamford, CT.

Region Region United States (USA)
Organisation Organisation FDA (US Food and Drug Administration)
  Group United States (govt)
Products Product Vitrakvi®
  Product 2 TRK inhibitor
Index term Index term Bayer–Loxo Oncology: TRK inhibitors, 201711– ww collab $400m upfront + $650m milestones developm of larotectinib + LOXO-195
Person Person LaCaze, Robert (Bayer 201702– EVP of new Oncology Strategic Business Unit joined 2015 from BMS)
     


   
Record changed: 2018-11-29

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Bayer (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC C Lee Hood Speaking 650x300px




» top